<DOC>
	<DOC>NCT00306696</DOC>
	<brief_summary>Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.</brief_summary>
	<brief_title>Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.</brief_title>
	<detailed_description>A randomised, open-label, parallel group study to evaluate the management of rosiglitazone-related fluid retention by investigating the effect of diuretics on plasma volume in subjects with type 2 diabetes mellitus treated for twelve weeks with rosiglitazone 4mg bd in addition to background anti-diabetic agents.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criteria: Subjects with type 2 diabetes. Stable FPG of &gt;=7.0 and &lt;=12.0mmol/L. Subjects had to have been established on SU treatment or SU+MET treatment for at least 2 months. Serum creatinine level &gt; 130 micromol/L. Exclusion criteria: Subjects taking &gt; 2 concomitant oral antidiabetic agents. Subjects with HbA1c &gt;=10%. Subjects already receiving diuretic medication. Subjects unstable or severe angina. CHF NYHA class iiv. Subjects with clinically significant hepatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>fluid retention</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>diuretics</keyword>
</DOC>